GSK

A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday.The initial…

On July 5, the World Health Organisation, UNICEF and Gavi, an organisation promoting vaccination, announced that 12 African countries would receive 18m doses of the world’s first malaria…

Exton, Pennsylvania, July 27, 2023 (GLOBE NEWSWIRE) -- While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and…

Budrul Chukrut | Lightrocket | Getty ImagesGlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company's new RSV vaccine to start off slower than it did for its…

Exton, Pennsylvania, July 20, 2023 (GLOBE NEWSWIRE) -- Nephrologists have long awaited the approval of HIF-PH inhibitors for the treatment of anemia in their chronic kidney disease (CKD)…

Respiratory syncytial virus vial.Manjurul | Istock | Getty ImagesThe Centers for Disease Control and Prevention on Thursday recommended that adults ages 60 and above receive a single dose of…

Respiratory syncytial virus vial.Manjurul | Istock | Getty ImagesVaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of…

A health worker prepares a flu vaccine shot before administering it to a local resident in Los Angeles, the United States, on Dec. 17, 2022.Xinhua News Agency | Getty ImagesAn advisory…

Respiratory syncytial virus viral vaccine under research.Hailshadow | Istock | Getty ImagesGlaxoSmithKline on Wednesday said its vaccine to protect adults ages 60 and older from respiratory…

Despite these historic approvals, GSK's supremacy in the unexplored RSV vaccine area is threatened by Pfizer, which is aggressively pursuing market share for its own RSV vaccine Abrysvo…